Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML

[1]  Shaohua Chen,et al.  Higher frequency of the CTLA‐4+LAG‐3+ T‐cell subset in patients with newly diagnosed acute myeloid leukemia , 2020, Asia-Pacific journal of clinical oncology.

[2]  Delong Liu,et al.  Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia , 2019, Biomarker Research.

[3]  Shaohua Chen,et al.  A skewed distribution and increased PD‐1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia , 2019, Journal of leukocyte biology.

[4]  P. Sharma,et al.  The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia , 2018, Cancer.

[5]  Sheng Wei,et al.  Dysfunction of immune system in the development of large granular lymphocyte leukemia , 2018, Hematology.

[6]  Yangqiu Li,et al.  T cell receptor-engineered T cells for leukemia immunotherapy , 2019, Cancer Cell International.

[7]  R. Gu,et al.  Molecular landscape and targeted therapy of acute myeloid leukemia , 2018, Biomarker Research.

[8]  S. Jiao,et al.  Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges , 2018, Cancer medicine.

[9]  Shaohua Chen,et al.  Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia , 2018, Journal of Hematology & Oncology.

[10]  Ling Xu,et al.  T cell senescence and CAR-T cell exhaustion in hematological malignancies , 2018, Journal of Hematology & Oncology.

[11]  Shaohua Chen,et al.  Increased exhausted CD8+ T cells with programmed death‐1, T‐cell immunoglobulin and mucin‐domain‐containing‐3 phenotype in patients with multiple myeloma , 2018, Asia-Pacific journal of clinical oncology.

[12]  H. Hetta,et al.  Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. , 2018, Cancer biomarkers : section A of Disease markers.

[13]  S. Gill,et al.  Novel Approaches to Acute Myeloid Leukemia Immunotherapy , 2018, Clinical Cancer Research.

[14]  P. Sharma,et al.  Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes , 2018, Leukemia.

[15]  G. Borthakur,et al.  Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges , 2018, Expert review of hematology.

[16]  S. Mineishi,et al.  Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients , 2018, Blood Cancer Journal.

[17]  D. Porter.  Advances in CAR T-cell therapy for chronic lymphocytic leukemia. , 2018, Clinical advances in hematology & oncology : H&O.

[18]  Jianxiang Wang,et al.  Precision therapy for acute myeloid leukemia , 2018, Journal of Hematology & Oncology.

[19]  Sen Jiang,et al.  Tim-3 Regulates Tregs’ Ability to Resolve the Inflammation and Proliferation of Acute Lung Injury by Modulating Macrophages Polarization , 2017, Shock.

[20]  Jessica M. Sido,et al.  CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. , 2017, Clinical immunology.

[21]  S. Zhang,et al.  Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia , 2017, PeerJ.

[22]  Xueyan Chen,et al.  Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis. , 2017, Clinics in laboratory medicine.

[23]  F. Mancini,et al.  Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia , 2017, Hematological oncology.

[24]  Ying Hu,et al.  TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance , 2017, Science Translational Medicine.

[25]  K. Davis,et al.  Checkpoint inhibition in pediatric hematologic malignancies , 2017, Pediatric hematology and oncology.

[26]  Shaohua Chen,et al.  Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[27]  Shaohua Chen,et al.  Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment , 2017, Oncotarget.

[28]  L. Varani,et al.  The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells , 2017, EBioMedicine.

[29]  Xiaopei Huang,et al.  Driving an improved CAR for cancer immunotherapy. , 2016, The Journal of clinical investigation.

[30]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[31]  T. Gebhardt,et al.  Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells , 2016, Front. Immunol..

[32]  Chaoying Ma,et al.  Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. , 2014, International journal of clinical and experimental pathology.

[33]  F. Craig,et al.  TIM3 expression by leukemic and non‐leukemic myeloblasts , 2013, Cytometry. Part B, Clinical cytometry.

[34]  K. Akashi,et al.  TIM‐3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia , 2012, Annals of the New York Academy of Sciences.

[35]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[36]  D. Munn,et al.  Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. , 2010, Blood.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..